• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
American Thyroid Association Statement on Surgical Application of Molecular Profiling for Thyroid Nodules: Current Impact on Perioperative Decision Making.美国甲状腺协会关于甲状腺结节分子谱分析手术应用的声明:对围手术期决策的当前影响。
Thyroid. 2015 Jul;25(7):760-8. doi: 10.1089/thy.2014.0502. Epub 2015 Jun 24.
2
Ultrasonographic features associated with malignancy in cytologically indeterminate thyroid nodules.超声特征与细胞学不确定的甲状腺结节中的恶性肿瘤相关。
Eur J Surg Oncol. 2014 Feb;40(2):182-6. doi: 10.1016/j.ejso.2013.11.015. Epub 2013 Dec 14.
3
Targeted Next Generation Sequencing with ThyroSeq v2.1 for Indeterminate Thyroid Nodules in Clinical Practice.临床实践中使用ThyroSeq v2.1对甲状腺结节进行二代测序靶向检测
Del Med J. 2016 Dec;88(12):366-372.
4
Response to "American Thyroid Association Statement on Surgical Application of Molecular Profiling for Thyroid Nodules: Current Impact on Perioperative Decision Making".对《美国甲状腺协会关于甲状腺结节分子谱分析的外科应用声明:对围手术期决策的当前影响》的回应
Thyroid. 2015 Nov;25(11):1265. doi: 10.1089/thy.2015.0372. Epub 2015 Sep 3.
5
A risk model to determine surgical treatment in patients with thyroid nodules with indeterminate cytology.一种用于确定甲状腺结节细针穿刺结果不确定患者手术治疗方案的风险模型。
Ann Surg Oncol. 2015 May;22(5):1527-32. doi: 10.1245/s10434-014-4190-8. Epub 2014 Nov 12.
6
Preoperative cytology with molecular analysis to help guide surgery for pediatric thyroid nodules.术前细胞学检查及分子分析以辅助指导儿童甲状腺结节的手术治疗。
Int J Pediatr Otorhinolaryngol. 2013 Oct;77(10):1697-700. doi: 10.1016/j.ijporl.2013.07.029. Epub 2013 Aug 9.
7
Fine needle aspiration of the thyroid: correlation with final histopathology in a surgical series of 797 patients.甲状腺细针抽吸:797 例外科系列患者的最终组织病理学相关性。
J Am Coll Surg. 2011 Jul;213(1):188-94; discussion 194-5. doi: 10.1016/j.jamcollsurg.2011.04.029. Epub 2011 May 20.
8
Does Hurthle cell lesion/neoplasm predict malignancy more than follicular lesion/neoplasm on thyroid fine-needle aspiration?在甲状腺细针穿刺中,嗜酸性细胞病变/肿瘤比滤泡性病变/肿瘤更能预测恶性肿瘤吗?
Diagn Cytopathol. 2006 May;34(5):330-4. doi: 10.1002/dc.20440.
9
Diagnostic lobectomy is not routinely required to exclude malignancy in thyroid nodules greater than four centimetres.对于直径大于4厘米的甲状腺结节,通常不需要进行诊断性肺叶切除术来排除恶性肿瘤。
ANZ J Surg. 2012 Jan-Feb;82(1-2):73-7. doi: 10.1111/j.1445-2197.2011.05667.x. Epub 2011 Feb 15.
10
Performance of the Afirma Gene Expression Classifier in Hürthle Cell Thyroid Nodules Differs from Other Indeterminate Thyroid Nodules.在 Hurthle 细胞甲状腺结节中,AfiRa 基因表达分类器的性能与其他不确定甲状腺结节不同。
Thyroid. 2015 Jul;25(7):789-96. doi: 10.1089/thy.2015.0049. Epub 2015 Jun 4.

引用本文的文献

1
Great Debate: Molecular Testing and Extent of Surgery in Well-Differentiated Thyroid Cancer.激烈辩论:高分化甲状腺癌的分子检测与手术范围
Ann Surg Oncol. 2025 Apr 29. doi: 10.1245/s10434-025-17348-z.
2
Prevalence and Clinical Impact of BRAF p.V600E Mutation in Papillary Thyroid Carcinoma.BRAF基因p.V600E突变在甲状腺乳头状癌中的患病率及临床影响
Endocr Pathol. 2025 Apr 16;36(1):13. doi: 10.1007/s12022-025-09859-y.
3
The clinicopathological landscape of thyroid cancer in South Africa-A multi-institutional review.南非甲状腺癌的临床病理概况——一项多机构综述
World J Surg. 2024 Dec;48(12):2863-2870. doi: 10.1002/wjs.12353. Epub 2024 Sep 22.
4
[Possibilities of the personalized approach to solitary thyroid nodules based on molecular profiling].基于分子谱分析的孤立性甲状腺结节个性化治疗方法的可能性
Chirurgie (Heidelb). 2024 Mar;95(3):179-185. doi: 10.1007/s00104-023-02002-9. Epub 2023 Dec 5.
5
Dynamic risk assessment in patients with differentiated thyroid cancer.分化型甲状腺癌患者的动态风险评估。
Rev Endocr Metab Disord. 2024 Feb;25(1):79-93. doi: 10.1007/s11154-023-09857-7. Epub 2023 Nov 28.
6
The value of Korean, American, and Chinese ultrasound risk stratification systems combined with BRAF(V600E) mutation for detecting papillary thyroid carcinoma in cytologically indeterminate thyroid nodules.联合韩国、美国和中国的超声风险分层系统与 BRAF(V600E) 突变检测在细胞学不确定的甲状腺结节中检测甲状腺乳头状癌的价值。
Endocrine. 2024 May;84(2):549-559. doi: 10.1007/s12020-023-03586-2. Epub 2023 Nov 9.
7
Evolving approaches in paediatric thyroid cytopathology: A review.儿科甲状腺细胞病理学的进展:综述
Cytopathology. 2024 Jan;35(1):60-69. doi: 10.1111/cyt.13311. Epub 2023 Sep 27.
8
Bilateral and Ipsilateral Central Neck Dissection in Total Thyroidectomy: a Long Term Comparison of Complications.全甲状腺切除术中双侧与同侧中央区颈部淋巴结清扫:并发症的长期比较
Indian J Otolaryngol Head Neck Surg. 2022 Dec;74(Suppl 3):6206-6212. doi: 10.1007/s12070-021-02904-2. Epub 2021 Oct 7.
9
Genetic and clinical profiles of 160 papillary thyroid cancers with lateral neck lymph node metastasis.160例伴有侧颈淋巴结转移的甲状腺乳头状癌的基因与临床特征
Front Oncol. 2023 Jan 12;12:1057532. doi: 10.3389/fonc.2022.1057532. eCollection 2022.
10
Integrated analysis of fibroblasts molecular features in papillary thyroid cancer combining single-cell and bulk RNA sequencing technology.结合单细胞和批量 RNA 测序技术对甲状腺乳头状癌成纤维细胞分子特征的综合分析。
Front Endocrinol (Lausanne). 2022 Oct 26;13:1019072. doi: 10.3389/fendo.2022.1019072. eCollection 2022.

本文引用的文献

1
Comprehensive genomic characterization of head and neck squamous cell carcinomas.头颈部鳞状细胞癌的综合基因组特征分析
Nature. 2015 Jan 29;517(7536):576-82. doi: 10.1038/nature14129.
2
Integrated genomic characterization of papillary thyroid carcinoma.甲状腺乳头状癌的综合基因组特征分析
Cell. 2014 Oct 23;159(3):676-90. doi: 10.1016/j.cell.2014.09.050.
3
Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next-generation sequencing assay.通过 ThyroSeq v2 下一代测序检测,对甲状腺结节滤泡性肿瘤/滤泡性肿瘤细胞学不典型的患者进行高度准确的癌症诊断。
Cancer. 2014 Dec 1;120(23):3627-34. doi: 10.1002/cncr.29038. Epub 2014 Sep 10.
4
Clinical application of molecular testing of fine-needle aspiration specimens in thyroid nodules.甲状腺结节细针穿刺标本分子检测的临床应用
Otolaryngol Clin North Am. 2014 Aug;47(4):557-71. doi: 10.1016/j.otc.2014.04.003. Epub 2014 Jun 12.
5
A clinical algorithm for fine-needle aspiration molecular testing effectively guides the appropriate extent of initial thyroidectomy.一项用于细针穿刺分子检测的临床算法可有效指导初始甲状腺切除术的适当范围。
Ann Surg. 2014 Jul;260(1):163-8. doi: 10.1097/SLA.0000000000000215.
6
PAX8/PPARγ rearrangement in thyroid nodules predicts follicular-pattern carcinomas, in particular the encapsulated follicular variant of papillary carcinoma.甲状腺结节中的PAX8/PPARγ重排可预测滤泡型癌,尤其是乳头状癌的包膜型滤泡变体。
Thyroid. 2014 Sep;24(9):1369-74. doi: 10.1089/thy.2014.0067. Epub 2014 Jul 16.
7
An independent study of a gene expression classifier (Afirma) in the evaluation of cytologically indeterminate thyroid nodules.一项关于基因表达分类器(Afirma)在评估细胞学不确定的甲状腺结节中的独立研究。
J Clin Endocrinol Metab. 2014 Nov;99(11):4069-77. doi: 10.1210/jc.2013-3584. Epub 2014 Apr 29.
8
Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer.鉴定转化的 STRN-ALK 融合基因为甲状腺癌侵袭性形式的潜在治疗靶点。
Proc Natl Acad Sci U S A. 2014 Mar 18;111(11):4233-8. doi: 10.1073/pnas.1321937111. Epub 2014 Feb 3.
9
Potential effects of molecular testing of indeterminate thyroid nodule fine needle aspiration biopsy on thyroidectomy volume.甲状腺结节细针穿刺活检结果不确定时进行分子检测对甲状腺切除范围的潜在影响。
World J Surg. 2014 Mar;38(3):634-8. doi: 10.1007/s00268-013-2430-x.
10
Malignancy rate in thyroid nodules classified as Bethesda category III (AUS/FLUS).甲状腺结节分类为贝塞斯达Ⅲ类(不典型/意义未明的滤泡性病变)的恶性率。
Thyroid. 2014 May;24(5):832-9. doi: 10.1089/thy.2013.0317. Epub 2014 Mar 10.

美国甲状腺协会关于甲状腺结节分子谱分析手术应用的声明:对围手术期决策的当前影响。

American Thyroid Association Statement on Surgical Application of Molecular Profiling for Thyroid Nodules: Current Impact on Perioperative Decision Making.

作者信息

Ferris Robert L, Baloch Zubair, Bernet Victor, Chen Amy, Fahey Thomas J, Ganly Ian, Hodak Steven P, Kebebew Electron, Patel Kepal N, Shaha Ashok, Steward David L, Tufano Ralph P, Wiseman Sam M, Carty Sally E

机构信息

1 Division of Head and Neck Surgery, Department of Otolaryngology, University of Pittsburgh Cancer Institute , Pittsburgh, Pennsylvania.

2 Department of Pathology, University of Pennsylvania Medical Center , Philadelphia, Pennsylvania.

出版信息

Thyroid. 2015 Jul;25(7):760-8. doi: 10.1089/thy.2014.0502. Epub 2015 Jun 24.

DOI:10.1089/thy.2014.0502
PMID:26058403
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4519104/
Abstract

BACKGROUND

Recent advances in research on thyroid carcinogenesis have yielded applications of diagnostic molecular biomarkers and profiling panels in the management of thyroid nodules. The specific utility of these novel, clinically available molecular tests is becoming widely appreciated, especially in perioperative decision making by the surgeon regarding the need for surgery and the extent of initial resection.

METHODS

A task force was convened by the Surgical Affairs Committee of the American Thyroid Association and was charged with writing this article.

RESULTS/CONCLUSIONS: This review covers the clinical scenarios by cytologic category for which the thyroid surgeon may find molecular profiling results useful, particularly for cases with indeterminate fine-needle aspiration cytology. Distinct strengths of each ancillary test are highlighted to convey the current status of this evolving field, which has already demonstrated the potential to streamline decision making and reduce unnecessary surgery, with the accompanying benefits. However, the performance of any diagnostic test, that is, its positive predictive value and negative predictive value, are exquisitely influenced by the prevalence of cancer in that cytologic category, which is known to vary widely at different medical centers. Thus, it is crucial for the clinician to know the prevalence of malignancy within each indeterminate cytologic category, at one's own institution. Without this information, the performance of the diagnostic tests discussed below may vary substantially.

摘要

背景

甲状腺癌发生机制的最新研究进展已将诊断性分子生物标志物和分析组合应用于甲状腺结节的管理。这些新型的、临床可用的分子检测的具体效用正得到广泛认可,尤其是在外科医生进行围手术期决策时,涉及手术必要性及初始切除范围。

方法

美国甲状腺协会外科事务委员会召集了一个特别工作组负责撰写本文。

结果/结论:本综述涵盖了甲状腺外科医生可能发现分子分析结果有用的按细胞学分类的临床情况,特别是对于细针穿刺细胞学结果不确定的病例。强调了每种辅助检测的独特优势,以传达这一不断发展领域的当前状况,该领域已显示出简化决策并减少不必要手术的潜力及附带益处。然而,任何诊断检测的性能,即其阳性预测值和阴性预测值,都受到该细胞学分类中癌症患病率的极大影响,已知不同医疗中心的患病率差异很大。因此,临床医生了解自己所在机构每个不确定细胞学分类中的恶性肿瘤患病率至关重要。没有这些信息,下面讨论的诊断检测的性能可能会有很大差异。